Cross-Border Impact Ventures: Investment Portfolio & Startup News
Cross-Border Impact Ventures
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
TidalSense secures £14m in funding from VCs to roll out AI-driven breath test for lung disease
TidalSense is a respiratory diagnostics business in Cambridge that has developed N-Tidal Diagnose, a handheld device and software combination which records a patient breathing normally for 75 seconds and applies AI models to detect chronic obstructive pulmonary disease. Intended for use in primary and community care by any trained healthcare professional, N-Tidal Diagnose removes the need for the forced exhalation and specialist supervision that conventional lung function testing requires.
OXcan raises £9m Series A led by We Venture Capital and Cross-Border Impact Ventures to revolutionise early lung cancer detection
OXcan develops blood-based liquid biopsy tests using proteomics and AI to detect lung cancer at earlier stages, enabling minimally invasive screening designed to improve outcomes and reduce pressure on healthcare systems.
More venture news
- 27 Oct 2026
LuthmoreLuthmore secures £5m from the FSE Group to roll out its battery-powered zero-emissions boiler
EquityIndustrial - 5 Nov 2026
Potential SciencesPotential Sciences launches from stealth with an eight figure investment led by UK Sovereign AI Fund and Twin Path Ventures for its frontier lab for chemistry
EquityLife Sciences - 4 Nov 2026
Crediflow AICrediflow AI raises £1.5m led by PXN Ventures to produce structured credit analysis for commercial lenders
EquityFintech
